Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2026 03:00 ET | Source: FoRx Therapeutics AG

FoRx Therapeutics Presents Preclinical Data at ACS Spring 2026, Confirming FORX-428's Potential for Best-in-Class PARG Inhibition

Presentation of the molecular structure, discovery, and preclinical data supporting the potential best-in-class profile of PARG inhibitor FORX-428.
December 18, 2025 02:00 ET | Source: FoRx Therapeutics AG

FoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG Inhibitor

FoRx Therapeutics closes an insider-led USD 50 million (CHF 40 million) Series A financing.
August 11, 2025 07:00 ET | Source: FoRx Therapeutics AG

FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response

Novel PARG inhibitor FORX-428 has shown best-in-class characteristics in preclinical studiesTrial initially taking place in the U.S., following IND clearanceInitial data expected in mid-2026 from...